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Abstract
Aim: To develop and test a new adverse drug reaction (ADR) causality assessment tool (CAT).
Methods: A comparison between seven assessors of a new CAT, formulated by an expert focus group, compared with the
Naranjo CAT in 80 cases from a prospective observational study and 37 published ADR case reports (819 causality
assessments in total).
Main Outcome Measures: Utilisation of causality categories, measure of disagreements, inter-rater reliability (IRR).
Results: The Liverpool ADR CAT, using 40 cases from an observational study, showed causality categories of 1 unlikely, 62
possible, 92 probable and 125 definite (1, 62, 92, 125) and ‘moderate’ IRR (kappa 0.48), compared to Naranjo (0, 100, 172, 8)
with ‘moderate’ IRR (kappa 0.45). In a further 40 cases, the Liverpool tool (0, 66, 81, 133) showed ‘good’ IRR (kappa 0.6) while
Naranjo (1, 90, 185, 4) remained ‘moderate’.
Conclusion: The Liverpool tool assigns the full range of causality categories and shows good IRR. Further assessment by
different investigators in different settings is needed to fully assess the utility of this tool.
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Introduction
Adverse drug reactions are a frequent source of morbidity and
mortality [1,2]. Causality assessment of ADRs may be undertaken
by clinicians, academics, pharmaceutical industry, regulators and
in different settings, including clinical trials [3,4,5,6]. At an
individual level, health care providers assess causality informally
when dealing with ADRs in patients to make decisions regarding
therapy. Regulatory authorities assess spontaneous ADR reports
[4,5] where causality assessment can help in signal detection and
aid in risk-benefit decisions regarding medicines [7,8].
An early paper by Sir Bradford Hill [9], describing minimum
criteria for establishing causality of adverse events, pre-dates the
earliest attempts to formulate ADR causality assessment tools.
Bradford Hill set out criteria for establishing causality which
included assessment of strength of the association, consistency of
the association, specificity, temporal relationship, biological
gradient (dose response), biological plausibility, coherence, exper-
imental evidence, and reasoning by analogy. Although these
criteria were not meant for ADRs, the elements have been adapted
in ADR causality tools. Indeed, attempts to formalise causality
assessment of ADRs into structured assessment tools have been
ongoing for more than 30 years [10,11]. It is known that assessing
ADR likelihood without a structure can lead to wide disagree-
ments between assessors [12]. These disagreements may be the
result of differing clinical backgrounds, specialties and experience.
The causality tools thus aim to limit disagreement between
assessors of ADR cases as to the likelihood that a reaction is related
to a particular medication taken by the patient. A large number of
causality tools have been developed ranging from the simple to the
complex, but none have gained universal acceptance [13].
One of the most widely used causality assessment tools is the
Naranjo tool [10]. This is a simple 10-item questionnaire that
classifies the likelihood that a reaction is related to a drug using
concepts such as timing, plausibility/evidence, de-challenge and
re-challenge/previous exposure. Each element of the question-
naire is weighted and the total score used to categorise the event
into unlikely, possible, probable and definite. The tool was
developed 30 years ago by adult pharmacologists/physicians and
psychiatrists. Published case reports were used to validate the
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been widely used, including recently in two prospective observa-
tional studies of ADRs causing hospital admission and occurring in
hospital in-patients [14,15]. However, the reliability of the
Naranjo tool has been questioned by a number of investigators
[3,8,16,17,18].
While undertaking a prospective observational study of ADRs in
children (in preparation), we found several difficulties with using
the Naranjo tool. When assessing this heterogeneous mix of
potential ADR cases, the investigators found some questions were
not appropriate, leading to many answers being categorised as
‘‘unknown’’. This led to lack of sensitivity as the overall score
obtained for each causality assessment may be artificially lowered,
which in turn underestimates the likelihood of an ADR. The
investigators encountered several cases which were unanimously
thought to be definite ADRs (e.g. repeated episodes of febrile
neutropenia during oncological chemotherapy) but which did not
reach the threshold for definite using the published Naranjo tool.
Moreover, the weighting for each question and the ADR
classification scoring boundaries used in the Naranjo tool were
not justified in the original publication, or subsequently.
Therefore, we undertook to develop a causality assessment tool
that would overcome some of these issues, while at the same time
(a) making it as easy, or easier, to use than the Naranjo tool; and
(b) ensuring that the basic principles of assessing causality as
defined by Bradford Hill were maintained.
Methods
Each of seven investigators (RG, JM, KB, MP, TN, RS, MT)
independently assessed the first 40 consecutive case reports from a
study of suspected ADRs causing hospital admission (ADRIC
Study 1 – adverse drug reactions in children available at http://
www.adric.org.uk/) using the Naranjo tool. The first 40 cases
assessed using Naranjo were reviewed in terms of the results of the
pair-wise agreements between the seven investigators. The cases
where major discrepancies occurred, that is, where the range of
causality probability differed by more than one category (e.g.
possible and definite), and the cases where close to half of the
raters differed from the others by one category were identified.
The questions within the Naranjo tool which caused the
discrepancies were identified and reviewed.
Each question in the Naranjo tool was reviewed by the
investigators at a consensus meeting to assess whether it was
appropriateto incorporate, discard or integrate with otherquestions
into a new, more appropriate, causality tool (Table 1). A new
causality tool was drawn up and modified through a consensus
approach between the seven investigators. The format of the new
tool was an algorithm, or flowchart, with dichotomous responses to
each decision followed by routing to further, specific questions,
rather than the weighted responses used in the Naranjo tool.
The new Liverpool ADR causality tool was then used to assess
20 new suspected ADR case reports from our observational study.
Table 1. Decisions made about questions within the Naranjo tool.
No. Naranjo tool questions Yes No Don’t know Outcome for Liverpool Tool
Q1 Are there previous conclusive reports
on this reaction?
+100 Retained – knowledge of previous reports can be important when assessing
if an adverse event is due to drug or disease.
Q2 Did the adverse event appear after
the suspected drug was administered?
+2 210 Modified – timing of event in relation to drug exposure is important when
determining causality.
Q3 Did the adverse reaction improve
when the drug was discontinued or
a specific antagonist was administered?
+100 Modified – Knowledge of de-challenge, if available, may provide further
evidence as to causality of an event. However, an event may have long-
lasting sequelae. A new question was added to the Liverpool tool to cover
this possibility.
Q4 Did the adverse reaction reappear
after the drug was readministered?
+2 210 Combined – Knowledge of re-challenge, if available, may add to the level of
certainty regarding causality assessment. This question is combined with
Naranjo Q8 regarding dose-response relationship to increasing dose. This can
also provide evidence to support or refute causality.
Q5 Are there alternative causes (other
than the drug) that could on their
own have caused the reaction?
21 +20 Modified – This question is replaced within the Liverpool tool by a question
involving likelihood of alternative cause, with an option to answer ‘unsure’
(which prompts the user to seek further evidence of the reaction). Naranjo
Q5 is worded such that it is difficult to answer No.
Q6 Did the reaction reappear when
a placebo was given?
21 +10 Rejected – With the exception of clinical trials, placebo use is not common
practice and this question is no longer relevant.
Q7 Was the drug detected in the blood
(or other fluids) in concentrations
known to be toxic?
+100 Modified – Objective evidence of the ADR occurrence will already be taken
in to account when the user is deciding whether the event is likely to be drug
or disease related. A question in the Liverpool tool asks for objective
evidence of likely ADR mechanism. If apparent, this may provide evidence of
causality to an assessor.
Q8 Was the reaction more severe when
the dose was increased, or less severe
when the dose was decreased?
+100 Combined – This question is combined with one addressing de-challenge in
the Liverpool tool. The answer to this question may be important in
establishing if there is a dose-response relationship between drug and
adverse event.
Q9 Did the patient have a similar reaction
to the same or similar drugs in any
previous exposure?
+100 Modified – this is included in the Liverpool algorithm, in relation to the
same drug(s) only, and given the same weighting as a positive re-challenge.
This may provide evidence of susceptibility, and likelihood, of the event
being related to a drug.
Q10 Was the adverse event confirmed by
any objective evidence?
+100 Modified – see Q7
doi:10.1371/journal.pone.0028096.t001
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of documentation. The collated causality categories for all seven
assessors showed 1 (0.7%) unlikely, 18 (12.9%) possible, 2 (1.4%)
probable and 119 (85%) definite. The assessors achieved moderate
agreement with a kappa of 0.51 (95% CI 0.19, 0.82). However,
there was an inappropriate bias towards the category of definite
which was caused by decision paths leading to an answer of
definite without the need for a positive re-challenge or previous
reaction with exposure to the same drug. The assessment tool was
reviewed again, and major discrepancies between scorers identi-
fied and each question within the algorithm reviewed to assess
usefulness. Questions and decision pathways that caused major
discrepancies were then modified. The new assessment tool was
then tested on a further 20 case reports; ten from the ADRIC
study and ten from an observational study of in-patient ADRs in
an adult hospital. Collated causality categories for the ten ADRIC
1 cases showed 0 (0%) unlikely, 24 (34%) possible, 39 (56%)
probable and 7 (10%) definite with a kappa of 0.27 (95% CI 0.11,
0.44). Collated causality categories for the ten adult cases showed 0
(0%) unlikely, 13 (19%) possible, 48 (69%) probable and 9 (13%)
definite with a kappa of 0.13 (95% CI 20.14, 0.38).
The results of these assessments prompted another review of the
appropriateness of the tool and questions. A third iteration was
used so that the development and evaluation of tool prototypes
was based on discussions in which 80 cases were used (Figure 1).
After the third iteration the investigators were satisfied with the
final version of the new tool (Figure 2) in terms of ease of use, lack
of ambiguity, and appropriateness of the causality assignment.
This was judged by expert opinion and consensus within the
group.
The assessment process for the Liverpool causality assessment
tool followed a step-wise procedure:
N The original 40 case reports (case reports of raw clinical data
from an observational study) initially assessed with Naranjo
were assessed by each of the seven investigators using the new
assessment tool to provide a comparison of the inter-rater
reliability between the two tools.
N In order to examine the tool using cases other than those
collected in our observational study, 37 cases of ADRs were
randomly selected from the Annals of Pharmacotherapy
(Figure S1) and independently evaluated by the seven assessors
using only the new tool. The Annals of Pharmacotherapy
requires authors to apply a Naranjo assessment prior to
publication of case reports.
N Since the original 40 cases from our observational study had
been used in the design of the new tool, a further new set of 40
ADR case reports from our study were then used to compare
inter-rater reliability using both the Naranjo and the Liverpool
tools.
Categorical scores from both the Naranjo tool and the new tool
take the same four point ordinal scale. The inter-rater agreements
at each stage of the assessment process were assessed using a linear
weighted kappa with 95% confidence intervals for ordered
categories. Exact agreement percentages (%EA) were computed
to measure the absolute concordances between assessor scores.
The percentage of extreme disagreement (%ED), where the
causality scores between two raters of the same case are wider than
one causality interval apart (e.g. definite for 1 rater and possible for
the other), were also computed to measure extreme disagreements
between pair-wise rater assessments. To supplement the pair-wise
kappas, a global kappa score measuring nominal scale agreement
across multiple assessors was calculated with 95% confidence
intervals [19]. The global kappa score provides a single statistic to
quantify assessor agreement for each set of cases. Kappa values
were interpreted according to the guidance from Altman [20]:
poor ,0.2; fair 0.21–0.40; moderate 0.41–0.60; good 0.61–0.80;
and very good 0.81–1.00 agreement.
Ethics Statement
The observational study of paediatric ADR admissions
(ADRIC) was conducted as a service evaluation and this aspect
of the study was felt, after discussion with the relevant bodies, not
to require an opinion from the Local Research Ethics Committee
or the hospital management.
Results
Assessment ofthe original40 consecutive ADR cases bytheseven
investigators using the Naranjo tool showed collated categorisation
of causality scores for all assessors (n=280 assessments) of 0 (0%)
unlikely,100 (36%)possible,172 (61%)probableand8(3%) definite
(Table 2). Exact agreement percentages for the pair-wise compar-
isons between raters rangedfrom 43%–93%. Percentage of extreme
disagreement (%ED) was 2.5% for four of the twenty-one pair-wise
comparisons. There were no extreme disagreements in 17/21 pair-
wise comparisons. Pair-wise kappas ranged from 0.27 to 0.86 and
the assessors achieved moderate inter-rater reliability with a global
kappa of 0.45 (95% CI 0.35–0.54) (Table 3). The same cases
Figure 1. Flowchart of the development of the Liverpool ADR
Causality Assessment Tool.
doi:10.1371/journal.pone.0028096.g001
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categoriesof1 (0.4%)unlikely,62(22%)possible, 92(33%)probable
and 125 (45%) definite. Exact agreement percentages ranged from
43–93%. All 21 pair-wise comparisons displayed extreme disagree-
ment with percentages ranging from 5–20%. Pair-wise kappas
ranged from 0.27 to 0.84 and the assessors achieved moderate inter-
rater reliability with a global kappa score of 0.48 (95% CI 0.42–
0.54) (Table 3).
The 37 randomly selected ADR case reports from the Annals of
Pharmacotherapy assessed by the seven investigators using the
Liverpool tool showed collated categorisation of causality scores
(n=259 assessments) of 1 (0.4%) unlikely, 67 (26%) possible, 136
(53%) probable and 55 (21%) definite. Exact agreement
percentages ranged from 57%–97%. 18/21 pair-wise comparisons
between raters showed some extreme disagreement, with the
percentage ranging from 5–11%, while three showed no extreme
disagreements. Pair-wise kappas ranged from 0.31 to 0.96 and the
assessors achieved moderate inter-rater reliability with a global
kappa of 0.43 (95% CI 0.34–0.51) (Table 4). These case reports
were not assessed by the investigators using the Naranjo tool as
The Annals of Pharmacotherapy requires authors to apply a
Naranjo assessment prior to publication of case reports in the
journal. The collated categorization of the case report author
assessments for the 37 cases showed 0 unlikely, 5 (14%) possible,
29 (78%) probable and 3 (8%) definite.
The 40 newly selected ADR cases assessed by the seven
investigators using the Naranjo tool showed collated categorisation
of causality scores (n=280 assessments) of 1 (0.4%) unlikely, 90
(32%) possible, 185 (66%) probable and 4 (1%) definite. Exact
agreement percentages ranged from 63%–90%. Percentage of
extreme disagreement was 2.5% for four pair-wise comparisons.
There were no extreme disagreements in 17/21 comparisons. The
Figure 2. Liverpool ADR causality assessment tool.
doi:10.1371/journal.pone.0028096.g002
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rater reliability and global kappa of 0.44 (95% CI 0.33–0.55)
(Table 5). The same cases assessed using the Liverpool tool showed
collated causality categories of 0 (0%) unlikely, 66 (24%) possible,
81 (29%) probable and 133 (48%) definite. Exact agreement
percentages ranged from 65%–88%. Percentage of extreme
disagreement ranged from 2.5–7.5% for 14 pair-wise comparisons.
There were no extreme disagreements in 7/21 comparisons. Pair-
wise kappas ranged from 0.51 to 0.85 and the assessors achieved
good inter-rater reliability with a global kappa of 0.60 (95% CI
0.54–0.67) (Table 5).
Discussion
A recent systematic review of studies assessing the reliability of
causality assessments concluded that ‘‘no causality assessment
method has shown consistent and reproducible measure of
causality.’’[3] We are currently undertaking a comprehensive
assessment of adverse drug reactions in children [21]. As part of
this, we had initially decided to use the Naranjo tool to assess
causality in our patients admitted with ADRs, and those who
developed ADRs as in-patients. In order to do this, we planned to
have assessments conducted independently by seven assessors.
Table 4. Liverpool ADR Causality tool assessment of 37 randomly selected published ADR case reports.
Assessor 2
RG JM KB MT TN MP RS
Assessor 1 RG %EA/ED 62.2/10.8% 64.9/10.8% 73.0/0% 56.8/8.1% 59.5/5.4% 67.6/5.4%
Kappa (95% CI) 0.307 (0.03,0.58) 0.38 (0.10,0.65) 0.65 (0.44,0.85) 0.32 (0.05,0.59) 0.41 (0.16,0.66) 0.46 (0.22,0.69)
JM %EA/ED 97.3/0% 62.2/10.8% 64.9/8.1% 56.8/8.1% 64.9/8.1%
Kappa (95% CI) 0.93 (0.82,1.00) 0.31 (0.04,0.59) 0.34 (0.06,0.61) 0.29 (0.02,0.57) 0.33 (0.09,0.57)
KB %EA/ED 59.5/10.8% 67.6/8.1% 59.5/8.1% 62.2/8.1%
Kappa (95% CI) 0.31 (0.03,0.59) 0.41 (0.13,0.68) 0.36 (0.10,0.63) 0.34 (0.10,0.58)
MT %EA/ED 64.9/8.1% 64.9/5.4% 78.4/5.4%
Kappa (95% CI) 0.40 (0.13,0.66) 0.48 (0.23,0.72) 0.61 (0.38,0.84)
TN %EA/ED 62.2/8.1% 67.6/5.4%
Kappa (95% CI) 0.38 (0.11,0.64) 0.42 (0.19,0.65)
MP %EA/ED 70.3/0%
Kappa (95% CI) 0.58 (0.38,0.77)
RS
Kappa scores outlined in bold demarcate either a good or very good level of agreement.
doi:10.1371/journal.pone.0028096.t004
Table 3. Naranjo and Liverpool tool assessment of 40 original ADR cases from an observational study.
Assessor 2
RG JM KB MT TN MP RS
Assessor 1 RG %EA/ED 57.5/0% 42.5/0% 55.0/0% 52.5/0% 62.5/0% 55.5/0%
Kappa (95%CI) 0.52 (0.27,0.77) 0.47 (0.21,0.73) 0.44 (0.19,0.69) 0.45 (0.21,0.69) 0.36 (0.09,0.62) 0.29 (0.04,0.54)
JM %EA/ED 57.5/5% 92.5/0% 70.0/0% 77.5/0% 72.5/0% 70.0/2.5%
Kappa (95%CI) 0.46 (0.26,0.67) 0.86 (0.71,1.00) 0.46 (0.22,0.69) 0.56 (0.34,0.78) 0.47 (0.19,0.75) 0.40 (0.15,0.65)
KB %EA/ED 42.5/10% 75.0/5% 77.5/0% 70.0/0% 70.0/0% 77.5/2.5%
Kappa (95%CI) 0.28 (0.08,0.49) 0.69 (0.52,0.87) 0.60 (0.39,0.81) 0.43 (0.19,0.66) 0.43 (0.15,0.71) 0.55 (0.32,0.77)
MT %EA/ED 55.0/7.5% 70.0/5% 57.5/7.5% 72.5/0% 62.5/0% 70.0/2.5%
Kappa (95%CI) 0.31 (0.06,0.56) 0.62 (0.45,0.80) 0.49 (0.31,0.67) 0.45 (0.20,0.70) 0.37 (0.11,0.62) 0.48 (0.23,0.73)
TN %EA/ED 52.5/7.5% 62.5/15% 52.5/20% 70.0/7.5% 70.0/0% 72.5/2.5%
Kappa (95%CI) 0.27 (0.07,0.46) 0.42 (0.21,0.62) 0.30 (0.10,0.50) 0.49 (0.26,0.72) 0.33 (0.05,0.62) 0.35 (0.06,0.63)
MP %EA/ED 62.5/5% 77.5/7.5% 67.5/12.5% 80.0/5% 80.0/7.5% 70.0/0%
Kappa (95%CI) 0.47 (0.25,0.69) 0.68 (0.49,0.86) 0.54 (0.33,0.74) 0.69 (0.49,0.89) 0.62 (0.39,0.84) 0.38 (0.11,0.65)
RS %EA/ED 55.5/10% 70.0/12.5% 62.5/15% 80.0/7.5% 75.0/10% 92.5/5%
Kappa (95%CI) 0.30 (0.05,0.55) 0.54 (0.32,0.76) 0.46 (0.24,0.67) 0.66 (0.44,0.87) 0.52 (0.27,0.76) 0.84 (0.66,1.00)
%EA/ED and Kappa scores in italics represent Naranjo tool analyses.
%EA/ED and Kappa scores in normal font represent Liverpool ADR causality tool analyses.
Kappa scores outlined in bold demarcate either a good or very good level of agreement.
doi:10.1371/journal.pone.0028096.t003
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Naranjo tool (as outlined in the introduction above), which led
us to develop the Liverpool Causality Assessment Tool.
The development of the Liverpool Causality Assessment Tool
involved an iterative process conducted by a multidisciplinary
team using raw case data and published case reports. The clinical
team included nurses, pharmacists and physicians, including those
working with adults and children. Previous experience with formal
ADR assessment ranged from minimal to advanced. The
assessment team comprised medical statisticians who focused
discussion on how to classify cases and monitored progress using
standard tools for inter-rater agreement. This approach has the
strength of timeliness but the potential weaknesses of ‘‘group-
think’’, in which independent thinking and expression of
differences may be lost in the pursuit of group cohesiveness.
We believe that the Liverpool Causality tool has several
advantages over the Naranjo tool. First, it performed as well as
the Naranjo tool with the first set of cases that were assessed. The
inter-rater reliability improved over time with the new tool,
whereas the inter-rater reliability when using Naranjo remained
similar, despite the fact that there was as much exposure to this
tool within the assessing group. The improved inter-rater
reliability with the new tool may be explained by increasing
experience of its use.
The proportion of exact agreements between assessors was
comparable between the two tools for both sets of cases despite the
improvement in the global kappa for the new tool. This is because
it is difficult to achieve a ‘definite’ category using the Naranjo tool
and assessors mainly scored cases as ‘possible’ or ‘probable.’
Therefore, the chances of exact agreement between two assessors
of the same case using the Naranjo tool are likely to be falsely
elevated compared to the kappa scores which adjust for chance
agreement. This paradox has been discussed previously in the
literature [22,23,24].
The percentage of extreme disagreement between raters was
higher for the Liverpool tool, when compared to Naranjo. Due to
the difficulty in achieving a ‘definite’ score with Naranjo the
chances of finding extreme disagreement, when comparing pair-
wise assessments, is likely to be falsely low. The observed
percentage of extreme disagreements decreased when using the
Liverpool tool from the first set of 40 cases to the last set. This may
also be explained by increasing experience of its use.
Second, the inter-rater reliability on assessing published case
reports with the new tool was similar to that when we assessed our
observational study cases with the Naranjo tool. Five of the seven
assessors work in paediatric practice and the published case reports
were adult cases. This perhaps provides an indication, albeit
indirectly, of the robustness of the tool in assessing a range of case
reports, even when used by assessors for cases from unfamiliar
clinical settings.
Third, in the Naranjo tool, almost all cases were categorised as
possible or probable. With the new tool, the range of categorisa-
tions was broader with some cases judged as being definite. A
novel aspect of the tool which made this possible was that prior
exposure that led to the same ADR, for example during a previous
course of chemotherapy, was included and was thus judged as
being equivalent to a prospective re-challenge. The high
proportion of definite causality assessments can be explained by
the fact that our study contained a large number of children with
malignancies who had repeated courses of chemotherapy. It is also
important to note that the cases were extracted from an
observational study of suspected ADRs in children, and thus
some case selection had occurred a priori making it improbable to
record a score of ‘unlikely’ when assessing with either tool.
Fourth, a flow diagram rather than scoring system was used in
the new tool for causality assessment and was felt by assessors to be
easy to follow and quick to complete. We used a classification
approach based on binary decisions (taking account of ‘‘don’t
know’’ responses). In this case, it is important to ensure that the
binary decisions are robust. Once this has been done, then the
instrument should be relatively context-independent. A weighted
scoring system, such as the Naranjo tool, however will give more
Table 5. Naranjo and Liverpool tool assessment of 40 new ADR cases from an observational study.
Assessor 2
RG JM KB MT TN MP RS
Assessor 1 RG %EA/ED 90.0/0% 80.0/0% 70.0/2.5% 75.0/0% 72.5/0% 62.5/0%
Kappa (95%CI) 0.81 (0.64,0.98) 0.61 (0.38,0.84) 0.46 (0.25,0.66) 0.51 (0.26,0.75) 0.46 (0.20,0.71) 0.23 (0.03,0.42)
JM %EA/ED 70.0/5% 75.0/0% 67.5/0% 80.0/0% 77.5/0% 62.5/0%
Kappa (95%CI) 0.62 (0.43,0.81) 0.49 (0.23,0.76) 0.45 (0.25,0.64) 0.59 (0.35,0.83) 0.54 (0.29,0.79) 0.22 (0.02,0.41)
KB %EA/ED 65.0/0% 77.5/2.5% 70.0/2.5% 80.0/0% 77.5/0% 67.5/0%
Kappa (95%CI) 0.62 (0.44,0.79) 0.73 (0.57,0.90) 0.40 (0.16,0.63) 0.56 (0.29,0.83) 0.50 (0.22,0.78) 0.19 (20.06,0.44)
MT %EA/ED 70.0/2.5% 75.0/5% 75.0/7.5% 70.0/2.5% 70.0/2.5% 72.5/0%
Kappa (95%CI) 0.63 (0.45,0.81) 0.70 (0.52,0.88) 0.64 (0.45,0.84) 0.367 (0.12,0.62) 0.40 (0.15,0.65) 0.25 (0.003,0.50)
TN %EA/ED 82.5/2.5% 77.5/2.5% 70.0/2.5% 82.5/0% 77.5/0% 77.5/0%
Kappa (95%CI) 0.77 (0.61,0.93) 0.73 (0.57,0.88) 0.61 (0.43,0.79) 0.79 (0.64,0.93) 0.48 (0.18,0.77) 0.38 (0.09,0.66)
MP %EA/ED 70.0/2.5% 80.0/2.5% 72.5/2.5% 80.0/0% 87.5/0% 80.0/0%
Kappa (95%CI) 0.63 (0.44,0.81) 0.75 (0.59,0.91) 0.64 (0.46,0.82) 0.76 (0.61,0.91) 0.85 (0.73,0.97) 0.41 (0.12,0.71)
RS %EA/ED 70.0/2.5% 70.0/5% 65.0/5% 80.0/0% 82.5/0% 75.0/0%
Kappa (95%CI) 0.60 (0.42,0.78) 0.57 (0.40,0.74) 0.50 (0.31,0.69) 0.73 (0.58,0.88) 0.77 (0.62,0.91) 0.67 (0.51,0.84)
%EA/ED and Kappa scores in italics represent Naranjo tool analyses.
%EA/ED and Kappa scores in normal font represent Liverpool ADR causality tool analyses.
Kappa scores outlined in bold demarcate either a good or very good level of agreement.
doi:10.1371/journal.pone.0028096.t005
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requires the validation of both the items in the tool and the
weightings themselves. Ideally, the weightings need to be
developed and validated in a context that is similar to the context
in which they are applied. Thus a weighting scheme is more likely
to be sensitive and specific within a defined context (as long as you
have a gold standard) but is more likely to be context-dependent.
Thus we would conclude, that for ADRs where many different
drugs can cause reactions in different settings, and where the
patient’s ADR may be assessed by healthcare professionals from a
variety of backgrounds, it is more important to develop a tool that
is context-independent.
Not unexpectedly, we were unable to achieve complete
agreement about causality assessment for a minority of suspected
ADRs. Most likely, this reflects underlying uncertainty arising
from issues such as the perceived likelihood of alternative
explanations. These perceptions will vary between raters depend-
ing on their experience or professional backgrounds.
In summary, we present a new causality assessment tool,
developed by a multi-disciplinary team, which performed better
than the Naranjo tool. We believe the new tool to be practicable
and likely to be acceptable for use by healthcare staff in assessing
ADRs. We have undertaken a validation of the tool, with a total of
819 causality assessments by seven investigators, using investiga-
tors within our ADRIC research programme. Although this
validation is equivalent, if not better, than that undertaken for
many other tools [10,25,26], one limitation is that the increase in
IRR for the second set of 40 case reports using the new tool
remains unexplained. We plan to investigate this using external
validation in a randomised clinical trial. Another limitation is that
the validation has been undertaken internally and not indepen-
dently by other investigators. However, we feel that the tool shows
promise, and by publishing it, we hope it will allow other
investigators to undertake independent assessments of the
usefulness of this tool in other populations (e.g. using data from
adult or elderly care settings), not only for spontaneous reports but
also for adverse events occurring within trials.
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